Latest Breaking News On - Bhushan akshikar - Page 1 : comparemela.com

GSK s Augmentin is India s no 1 drug brand

Research firm PharmaTrac data shows Augmentin sales at Rs 801 crore from November 2022-23. For the month of November, Augmentin sales stood at Rs 75 crore. It has shown a moving annual total (MAT) growth growth of 12.3%. As per the data, Glycomet GP sales stood at Rs 774 crore from same period and the sales for November stood at Rs 64 crore. It has shown a MAT growth of 7.5%.

New delhiBhushan akshikarSheetal sapaleAugmentin amoxycillinOral antidiabetic drugAntibiotic drug augmentinDoctor fraternityGlycomet gpGsk pharmaceuticalsAntidiabetic drug market

GSK India Q2 Results: Net profit grows 11% YoY to Rs 216 crore

Our Q2 performance reflects an overall recovery with market share gains in several key promoted brands across all business units. We held leadership position for our key brands in relevant therapy areas such as anti-infectives and dermatology," said Bhushan Akshikar, MD of GSK India

Bhushan akshikarGlaxosmithkline pharmaceuticalsGsk india q2 resultsGsk india q2Gsk india resultsGsk indiaGsk india earningsGsk india shares

GSK s India unit posts Q2 profit rise on strong vaccine demand

GlaxoSmithKline Pharmaceuticals reported a 12.5% rise in quarterly profit on Thursday as the Indian unit of UK's GSK plc saw strong demand for its vaccines and general medicine. Consolidated profit for the quarter ended September 30 rose to 2.18 billion rupees ($26.18 million) from 1.93 billion rupees a year earlier. Sales of general medicine grew 5% during the quarter, while those of vaccines rose 10% led by demand for its shingles vaccine, Shingrix, the company said in a statement.

United kingdomUnited statesAshna teresa brittoBhushan akshikarNivedita bhattacharjeeGlaxosmithkline pharmaceuticalsSmithkline pharmaceuticalsNifty pharmaIndian rupeesGsk plcShingles vaccine

GSK s India arm posts 12 5% Q2 profit at Rs 218 cr on strong vaccine demand

GSK s India arm posts 12 5% Q2 profit at Rs 218 cr on strong vaccine demand
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomBhushan akshikarGlaxosmithkline pharmaceuticalsNifty pharma

gsk india: GSK India net profit grows 13% to Rs 131 crore in Q1FY24

GlaxoSmithKline Pharmaceuticals (GSK India) on Wednesday reported 13% year-on-year (YoY) jump of net profit to Rs 131 crore for the quarter ended June 2023 led by robust volumes, price hikes and recovery of its vaccine business. The said it maintained its gross margins despite the National List of Essential Medicines (NLEM) impact, while EBITDA margins declined 1% to 19.1% on account of new product launch investments led by Shingrix.

Bhushan akshikarNational list of essential medicinesGlaxosmithkline pharmaceuticalsSmithkline pharmaceuticalsNational listEssential medicinesHerpes zosterGsk indiaVaccine businessNet profitRevenue growthPrice hikes